Laihdutuslääke

About us

This medical project is dedicated to the systematic study of the efficacy and duration of action of medicines used in the treatment of obesity. The aim is to objectively evaluate how a weight loss medication can affect weight reduction, maintenance of achieved results, and patients’ overall health during long-term use.

The project examines key formulations currently used in clinical practice: Mysimba (naltrexone + bupropion), Saxenda (liraglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), Qsiva (phentermine + topiramate), Orlistat, as well as Ozempic and Rybelsus (semaglutide in different forms). Special attention is given to both the early dynamics of weight loss and the long-term sustainability of results, even after treatment has ended.

Based on the findings, the project aims to provide recommendations for healthcare use and to strengthen understanding of the role that weight loss medication can play in obesity.